×
About 5,070 results

ALLMedicine™ Clostridium Difficile Infection Center

Research & Reviews  1,575 results

An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection
https://clinicaltrials.gov/ct2/show/NCT03988855

May 10th, 2022 - This is an open-label study to evaluate the safety, efficacy, and PK of DNV3837 at a dose of 1.5 mg/kg actual body weight(BW)/day administered via IV infusion in subjects with CDI. The study will be conducted in 2 subsequent parts. In Part 1 of th...

Fecal Transplantation for Primary Clostridium Difficile Infection
https://clinicaltrials.gov/ct2/show/NCT03796650

Apr 29th, 2022 - Up to one third of patients with clostridium difficile infection treated with antibiotics experience recurrent or relapsing symptoms within a few weeks. Even with subsequent antibiotic treatment, multiple recurrences/relapses are frequent. Fecal m...

Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2
https://clinicaltrials.gov/ct2/show/NCT03838601

Apr 22nd, 2022 - Past findings suggest oral microbiome might be used to predict recurrence and response to therapies, as past studies have shown surgery, radiotherapy and chemotherapy alter the microbiome, which in turn modulates treatment effectiveness/toxicity. ...

Extrapancreatic Complications in Hospitalized Patients With Mild Acute Pancreatitis Are...
https://doi.org/10.1097/MPA.0000000000001986
Pancreas Shah I, Yakah W et. al.

Apr 12th, 2022 - Patients with acute pancreatitis (AP) are at risk for extrapancreatic complications (EPCs) when admitted to the intensive care unit (ICU). We assessed the prevalence of EPCs in non-ICU AP patients and their outcomes. We retrospectively studied EPC...

Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years
https://clinicaltrials.gov/ct2/show/NCT04026009

Apr 7th, 2022 - The purpose of this study is to generate safety, reactogenicity (assessment of any expected or unexpected side effect of the vaccine) and immunogenicity (ability to induce an immune response) data for the development of a candidate Clostridium dif...

see more →

Guidelines  5 results

The use of faecal microbiota transplant as treatment for recurrent or refractory Clostr...
https://doi.org/10.1016/j.jhin.2018.07.037
The Journal of Hospital Infection; Mullish BH, Quraishi MN et. al.

Sep 4th, 2018 - The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.|20...

The use of faecal microbiota transplant as treatment for recurrent or refractory Clostr...
https://doi.org/10.1136/gutjnl-2018-316818
Gut Mullish BH, Quraishi MN et. al.

Aug 30th, 2018 - Interest in the therapeutic potential of faecal microbiota transplant (FMT) has been increasing globally in recent years, particularly as a result of randomised studies in which it has been used as an intervention. The main focus of these studies ...

Diagnostic stewardship and the 2017 update of the IDSA-SHEA Clinical Practice Guideline...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066535
Diagnosis (Berlin, Germany); Madden GR, Poulter MD et. al.

Jul 11th, 2018 - Diagnostic stewardship and the 2017 update of the IDSA-SHEA Clinical Practice Guidelines for Clostridium difficile Infection.|2018|Madden GR,Poulter MD,Sifri CD,|methods,isolation & purification,diagnosis,microbiology,epidemiology,microbiology,eth...

Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018983
Clinical Infectious Diseases : an Official Publication Of... McDonald LC, Gerding DN et. al.

Feb 21st, 2018 - A panel of experts was convened by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) to update the 2010 clinical practice guideline on Clostridium difficile infection (CDI) in adults. The u...

Practice parameters for the management of Clostridium difficile infection.
https://doi.org/10.1097/DCR.0000000000000289
Diseases of the Colon and Rectum; Steele SR, McCormick J et. al.

Dec 10th, 2014 - Practice parameters for the management of Clostridium difficile infection.|2014|Steele SR,McCormick J,Melton GB,Paquette I,Rivadeneira DE,|adverse effects,therapeutic use,diagnosis,prevention & control,therapy,pathogenicity,methods,therapeutic use,

see more →

Drugs  4 results see all →

Clinicaltrials.gov  64 results

An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection
https://clinicaltrials.gov/ct2/show/NCT03988855

May 10th, 2022 - This is an open-label study to evaluate the safety, efficacy, and PK of DNV3837 at a dose of 1.5 mg/kg actual body weight(BW)/day administered via IV infusion in subjects with CDI. The study will be conducted in 2 subsequent parts. In Part 1 of th...

Fecal Transplantation for Primary Clostridium Difficile Infection
https://clinicaltrials.gov/ct2/show/NCT03796650

Apr 29th, 2022 - Up to one third of patients with clostridium difficile infection treated with antibiotics experience recurrent or relapsing symptoms within a few weeks. Even with subsequent antibiotic treatment, multiple recurrences/relapses are frequent. Fecal m...

Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2
https://clinicaltrials.gov/ct2/show/NCT03838601

Apr 22nd, 2022 - Past findings suggest oral microbiome might be used to predict recurrence and response to therapies, as past studies have shown surgery, radiotherapy and chemotherapy alter the microbiome, which in turn modulates treatment effectiveness/toxicity. ...

Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years
https://clinicaltrials.gov/ct2/show/NCT04026009

Apr 7th, 2022 - The purpose of this study is to generate safety, reactogenicity (assessment of any expected or unexpected side effect of the vaccine) and immunogenicity (ability to induce an immune response) data for the development of a candidate Clostridium dif...

Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection
https://clinicaltrials.gov/ct2/show/NCT04138706

Apr 6th, 2022 - STUDY POPULATION This is a multi-centre study involving institutions in British Columbia, Ontario and Quebec. The study population will be drawn from patients cared for as inpatients or outpatients at the participating hospitals. Such patients wil...

see more →

News  380 results

More Selective Antibiotic Shows Promise for C difficile Infection
https://www.medscape.com/viewarticle/973563

May 6th, 2022 - An investigational, novel oral antibiotic with greater selectivity than vancomycin, metronidazole, and even fidaxomicin may offer improved protection of healthy gut bacteria during the treatment of Clostridium difficile infection (CDI), according ...

Fecal Transplantation, Boosted by Fiber, Improves Insulin in Obesity
https://www.medscape.com/viewarticle/954783

Jul 14th, 2021 - As use of fecal microbial transplantation evolves, new research shows that a noninvasive approach ― with an oral capsule formulation ― combined with fiber supplementation significantly improved insulin sensitivity among those with severe obesity a...

Ibrutinib/Palbociclib Combo Shows Activity in Previously Treated MCL
https://www.onclive.com/view/ibrutinibpalbociclib-combo-shows-activity-in-previously-treated-mcl

Dec 4th, 2020 - Peter Martin, MD Combining ibrutinib (Imbruvica) with the CDK4/6 inhibitor palbociclib (Ibrance) appeared to be well tolerated and active in patients with previously treated mantle cell lymphoma, according to phase I data. 1 Results of the dose-...

12 Highlights You Should Know From DDW 2020
https://www.medscape.com/viewarticle/931345

Jun 1st, 2020 - This transcript has been edited for clarity. Hello. I'm Dr David Johnson, professor of medicine and chief of gastroenterology at Eastern Virginia Medical School in Norfolk, Virginia. Digestive Disease Week (DDW) 2020 did not pan out as intended, w...

12 Highlights You Should Know From DDW 2020
https://www.staging.medscape.com/viewarticle/931345

Jun 1st, 2020 - This transcript has been edited for clarity. Hello. I'm Dr David Johnson, professor of medicine and chief of gastroenterology at Eastern Virginia Medical School in Norfolk, Virginia. Digestive Disease Week (DDW) 2020 did not pan out as intended, w...

see more →